Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.12.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Emmanuelle Samalin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Institut de …. Hauptthemen laut MEDLINE: Cetuximab, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Irinotecan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Triplet chemotherapy plus cetuximab showed promising results in phase II trials in unsystematically selected RAS population. We evaluated FOLFIRINOX+cetuximab efficacy as first-line treatment in extended RAS wild-type metastatic colorectal cancer (mCRC) patients. METHODS: We retrospectively analyzed patients treated with FOLFIRINOX+cetuximab, using data from clinical trials and real-life practice. Extended mutation analysis was performed when RAS/BRAF status was unavailable. The primary endpoint was progression-free survival (PFS). RESULTS: Seventy patients (61.4 % male, median age 58.7 years) were analyzed. Eighty percent had left-sided mCRC and 97.1 % had liver metastases. Median PFS and overall survival (OS) were 13.3 and 48.5 months, respectively. The objective response rate was 85.7 %, with 20 % complete response. Primary tumor location did not affect OS and PFS. BRAF wild-type patients (n = 65) had longer PFS (13.3 vs. 6.0 months; p = 0.005) and OS (50.1 vs. 21.2 months; p = 0.007) than BRAF mutated patients (n = 5, including four BRAFV600E). Median OS was significantly longer in resected patients (n = 39, 55.1 vs. 30.7 months; p = 0.030). Main toxicities were diarrhea (31.4 %) and neutropenia (21.4 %). CONCLUSION: FOLFIRINOX+cetuximab provides good PFS, high response rate and prolonged disease control in initially unresectable extended RAS wild-type mCRC. This combination is particularly interesting for selected patients with liver-limited disease eligible to secondary resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Institut de Génomique Fonctionnelle, CNRS, INSERM, Univ. Montpellier, Montpellier,…
- Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpelli…
- Oncology Department, Institut du Cancer de Montpellier, Univ. Montpellier (ICM), 208 avenue des Apothicaires, Montpellier 34298, France; Digestive Oncology Department, CHU Montpellier, Univ. Montpellier, Montpellier, Fr…
- INSERM CIC-P 1401, Univ. Bordeaux, Bordeaux PharmacoEpi, Bordeaux 33000, France.
- Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France.
- Medical Oncology Department, CHU Toulouse, Toulouse, France.
Zitieren
APA
Samalin, E., Mazard, T., Assenat, E., Rouyer, M., de la Fouchardière, C., Guimbaud, R., Smith, D., Portales, F., Ychou, M., Adenis, A., Fiess, C., Lopez-Crapez, E., & Thezenas, S. (2024). Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.12.018
Vancouver
Samalin E, Mazard T, Assenat E, Rouyer M, de la Fouchardière C, Guimbaud R, et al. Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.12.018
BibTeX
@article{Samalin2024,
author = {Samalin, Emmanuelle and Mazard, Thibault and Assenat, Eric and Rouyer, Magali and de la Fouchardière, Christelle and Guimbaud, Rosine and Smith, Denis and Portales, Fabienne and Ychou, Marc and Adenis, Antoine and Fiess, Catherine and Lopez-Crapez, Evelyne and Thezenas, Simon},
title = {Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.12.018}
}
EUVIMED